Trial site
Indywidualna Specjalistyczna Praktyka Lekarska Agnieszka Remlinger Molenda
Suchy Las, 62-002, PolandEU-13 widening countryNot linked to an institution yet
- 5running trials
- 8closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 23 trials
- Phase 2/31 trial
- Status
- Completed8 trials
- Not yet recruiting2 trials
- Recruiting2 trials
- Active, not recruiting1 trial
- Lead sponsor
- Janssen Cilag International3 trials
- Compass Pathfinder Limited1 trial
- Draig Therapeutics Limited1 trial
- Eli Lilly and Company1 trial
- Janssen Pharmaceutica N.V., Belgium1 trial
- and 6 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
2024-511057-22-00· Phase 3· Janssen Cilag International· Source
Completed
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant
2024-511557-21-00· Phase 3· Janssen Cilag International· Source
Completed
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
NCT06029439· Phase 3· Neumora Therapeutics Inc.· Source
Completed
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039· Phase 3· Neumora Therapeutics, Inc.· Source
Completed
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.
2023-508163-74-00· Phase 3· Janssen Cilag International· Source
Completed
Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.
2022-500538-27-00· Phase 2/3· Otsuka Pharmaceutical Development And Commercialization Inc.· Source
Completed
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05550532· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study of JNJ-55308942 in the Treatment of Bipolar Depression
NCT05328297· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source
Report an error